NASDAQ:PDLI - PDL Biopharma Stock Price, Price Target & More

PDL Biopharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL Biopharma announced that its board has approved a stock buyback plan on Monday, September 25th 2017, which permits the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its shares are undervalued.

PDL Biopharma (NASDAQ:PDLI) posted its earnings results on Thursday, March, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $68.04 million for the quarter. PDL Biopharma had a return on equity of 11.76% and a net margin of 33.57%. View PDL Biopharma's Earnings History.

PDL Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for PDL Biopharma.

2 analysts have issued 1-year price targets for PDL Biopharma's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate PDL Biopharma's share price to reach $3.50 in the next twelve months. View Analyst Ratings for PDL Biopharma.

Some companies that are related to PDL Biopharma include Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Solid Biosciences (SLDB), Novavax (NVAX) and Voyager Therapeutics (VYGR).

Media headlines about PDLI stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDL Biopharma earned a coverage optimism score of 0.01 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

PDL Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.62%), Dimensional Fund Advisors LP (7.60%), Northern Trust Corp (3.28%), Schwab Charles Investment Management Inc. (2.26%), Royal Bank of Canada (1.84%) and Kestrel Investment Management Corp (1.08%). View Institutional Ownership Trends for PDL Biopharma.

PDLI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Seizert Capital Partners LLC, JPMorgan Chase & Co., California Public Employees Retirement System, Prudential Financial Inc., Federated Investors Inc. PA, Citigroup Inc. and BlackRock Inc.. View Insider Buying and Selling for PDL Biopharma.

PDLI stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Schwab Charles Investment Management Inc., SG Americas Securities LLC, Mackay Shields LLC, Element Capital Management LLC and UBS Group AG. View Insider Buying and Selling for PDL Biopharma.

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PDLI stock can currently be purchased for approximately $2.81.

PDL Biopharma has a market capitalization of $417.27 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL Biopharma employs 87 workers across the globe.

PDL Biopharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]